• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基因操作与细胞免疫疗法联合治疗癌症

The Gene Manipulation and Cellular Immunotherapy Combination in the Treatment of Cancer.

作者信息

Khatami Fatemeh, Aghamir Zahra Sadat, Jahanshahi Fatemeh, Feiz-Abadi Seyed Ariana, Birang Fatemeh, Khoshchehreh Mahdi, Namazi Shabestari Alireza, Aghamir Seyed Mohammad Kazem

机构信息

Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Faculty of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Iran J Biotechnol. 2022 Apr 1;20(2):e3094. doi: 10.30498/ijb.2022.294933.3094. eCollection 2022 Apr.

DOI:10.30498/ijb.2022.294933.3094
PMID:36337063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9583824/
Abstract

CONTEXT

The immune system is directly linked to the tumors, from tumor formation to the tumor's development and metastasis. So, the interest of scientists over the protective immunological mechanisms has increased and shown gifted strategy in cancer treatment.

EVIDENCE ACQUISITION

Genetic engineering and cellular immunotherapy are two different advanced molecular mechanisms to modify the immune responses and genome. Gene manipulation is the bioengineering technology that allows vectors to transfer new genetic information into the target cells. Cellular immunotherapy is an excellent strategy that connects the body's immune system to fight cancer.

RESULTS & CONCLUSIONS: This review described that combination of genetic engineering and cellular immunotherapy has brought the novel antitumor repressive molecules stopping the tumor tissue immune tolerance and significantly expanding cancer therapy's effectiveness. Usually, cell immunotherapy and genetic engineering are considered two independent processes, and, in this review, we believe them in combinations. Here, we review these two novel approaches, and they are both combinations in terms of technological advances and clinical experience.

摘要

背景

免疫系统与肿瘤直接相关,从肿瘤形成到肿瘤发展及转移。因此,科学家对保护性免疫机制的兴趣增加,并在癌症治疗中展现出了有前景的策略。

证据获取

基因工程和细胞免疫疗法是两种不同的先进分子机制,用于调节免疫反应和基因组。基因操作是一种生物工程技术,可使载体将新的遗传信息转移到靶细胞中。细胞免疫疗法是一种将机体免疫系统与抗癌作用联系起来的卓越策略。

结果与结论

本综述表明,基因工程与细胞免疫疗法的联合带来了新型抗肿瘤抑制分子,可阻止肿瘤组织的免疫耐受,并显著提高癌症治疗的效果。通常,细胞免疫疗法和基因工程被视为两个独立的过程,而在本综述中,我们认为它们可以联合使用。在此,我们对这两种新方法进行综述,它们在技术进步和临床经验方面均为联合应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b831/9583824/a8dc824d18cc/IJB-20-e3090-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b831/9583824/26d8941cf65a/IJB-20-e3090-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b831/9583824/c125af1091f6/IJB-20-e3090-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b831/9583824/3070f29ef311/IJB-20-e3090-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b831/9583824/4f1220d8ecf0/IJB-20-e3090-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b831/9583824/a8dc824d18cc/IJB-20-e3090-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b831/9583824/26d8941cf65a/IJB-20-e3090-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b831/9583824/c125af1091f6/IJB-20-e3090-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b831/9583824/3070f29ef311/IJB-20-e3090-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b831/9583824/4f1220d8ecf0/IJB-20-e3090-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b831/9583824/a8dc824d18cc/IJB-20-e3090-g005.jpg

相似文献

1
The Gene Manipulation and Cellular Immunotherapy Combination in the Treatment of Cancer.基因操作与细胞免疫疗法联合治疗癌症
Iran J Biotechnol. 2022 Apr 1;20(2):e3094. doi: 10.30498/ijb.2022.294933.3094. eCollection 2022 Apr.
2
Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.嵌合抗原受体工程:过继细胞免疫治疗进化过程中的正确步骤。
Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419.
3
Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.嵌合抗原受体(CAR)修饰的自然杀伤细胞在癌症和艾滋病中的免疫治疗及免疫突触形成
Protein Cell. 2017 Dec;8(12):861-877. doi: 10.1007/s13238-017-0415-5. Epub 2017 May 9.
4
Systemic Immunostimulatory Effects of Radiation Therapy Improves the Outcomes of Patients With Advanced NSCLC Receiving Immunotherapy.放疗的全身免疫刺激作用改善了接受免疫治疗的晚期 NSCLC 患者的结局。
Am J Clin Oncol. 2020 Mar;43(3):218-228. doi: 10.1097/COC.0000000000000651.
5
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential.嵌合抗原受体工程化自然杀伤细胞:具有巨大潜力的癌症免疫治疗新武器。
Exp Hematol Oncol. 2022 Nov 2;11(1):85. doi: 10.1186/s40164-022-00341-7.
6
The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.免疫突触在预测嵌合抗原受体 (CAR) 免疫疗法疗效中的作用。
Cell Commun Signal. 2020 Aug 25;18(1):134. doi: 10.1186/s12964-020-00617-7.
7
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.自然杀伤细胞:癌症免疫治疗成功的关键。
Front Immunol. 2021 Apr 28;12:679117. doi: 10.3389/fimmu.2021.679117. eCollection 2021.
8
Clinically feasible approaches to potentiating cancer cell-based immunotherapies.增强基于癌细胞的免疫疗法的临床可行方法。
Hum Vaccin Immunother. 2015;11(4):851-69. doi: 10.1080/21645515.2015.1009814.
9
Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy.瞬时细胞-细胞形成是肿瘤复发和免疫治疗耐药的基础。
Elife. 2022 Sep 20;11:e80315. doi: 10.7554/eLife.80315.
10
Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.自然杀伤细胞的病毒和非病毒工程作为新兴的过继性癌症免疫疗法。
J Immunol Res. 2018 Sep 17;2018:4054815. doi: 10.1155/2018/4054815. eCollection 2018.

引用本文的文献

1
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.溶瘤病毒和嵌合抗原受体T细胞基因治疗进展及治疗相关分组
Curr Issues Mol Biol. 2025 Apr 10;47(4):268. doi: 10.3390/cimb47040268.
2
Deciphering the Role of Cancer Stem Cells: Drivers of Tumor Evolution, Therapeutic Resistance, and Precision Medicine Strategies.解读癌症干细胞的作用:肿瘤进化、治疗抗性及精准医学策略的驱动因素
Cancers (Basel). 2025 Jan 24;17(3):382. doi: 10.3390/cancers17030382.
3
Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma.

本文引用的文献

1
Advances in Immunotherapy of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤免疫治疗的进展
Onco Targets Ther. 2021 Aug 14;14:4477-4484. doi: 10.2147/OTT.S317434. eCollection 2021.
2
The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer.纳武利尤单抗联合免疫治疗和/或化疗在晚期非小细胞肺癌一线治疗中的作用。
Expert Opin Biol Ther. 2021 Mar;21(3):303-309. doi: 10.1080/14712598.2021.1869209. Epub 2020 Dec 31.
3
CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer.
腺相关病毒(AAV)作为基因治疗剂在肝细胞癌中的最新进展。
Virol J. 2024 Jan 12;21(1):17. doi: 10.1186/s12985-024-02286-1.
CRISPR/Cas:从肿瘤基因编辑到基于T细胞的癌症免疫疗法
Front Immunol. 2020 Sep 29;11:2062. doi: 10.3389/fimmu.2020.02062. eCollection 2020.
4
Current Microsatellite Instability Testing in Management of Colorectal Cancer.当前结直肠癌管理中的微卫星不稳定性检测。
Clin Colorectal Cancer. 2021 Mar;20(1):e12-e20. doi: 10.1016/j.clcc.2020.08.001. Epub 2020 Aug 10.
5
CAR-NK cells: A promising cellular immunotherapy for cancer.嵌合抗原受体自然杀伤细胞:癌症有前途的细胞免疫疗法。
EBioMedicine. 2020 Sep;59:102975. doi: 10.1016/j.ebiom.2020.102975. Epub 2020 Aug 24.
6
Engineered off-the-shelf therapeutic T cells resist host immune rejection.工程化现成的治疗性 T 细胞能抵抗宿主免疫排斥。
Nat Biotechnol. 2021 Jan;39(1):56-63. doi: 10.1038/s41587-020-0601-5. Epub 2020 Jul 13.
7
Immunotherapy in Prostate Cancer.前列腺癌的免疫疗法
Cancers (Basel). 2020 Jul 1;12(7):1752. doi: 10.3390/cancers12071752.
8
A guide to cancer immunotherapy: from T cell basic science to clinical practice.癌症免疫疗法指南:从 T 细胞基础科学到临床实践。
Nat Rev Immunol. 2020 Nov;20(11):651-668. doi: 10.1038/s41577-020-0306-5. Epub 2020 May 20.
9
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.双特异性 CAR-T 细胞靶向 CD19 和 CD22 治疗复发或难治性 B 细胞急性淋巴细胞白血病成人患者。
J Hematol Oncol. 2020 Apr 3;13(1):30. doi: 10.1186/s13045-020-00856-8.
10
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.激发针对NY-ESO-1癌胚抗原的免疫反应,将其作为癌症免疫治疗的潜在靶点。
J Transl Med. 2020 Mar 27;18(1):140. doi: 10.1186/s12967-020-02306-y.